Table 2.
Unadjusted rates of SARS-CoV-2 infection and severe outcome by vaccine group
| Outcome | Unvaccinated | One Dosea | Two Dosesb |
|---|---|---|---|
| Follow-up for infection, daysc | 1,398,544 | 424,427 | 563,396 |
| SARS-CoV-2 infections, n | 488 | 112 | 63 |
| Infection rate per 100,000 days | 34.9 | 26.4 | 11.2 |
| Follow-up for severe outcome, days | 1,403,562 | 426,643 | 564,927 |
| Hospitalizations, n (% of cases) | 253 (52) | 51 (46) | 19 (30) |
| Hospitalization rate per 100,000 days | 17.6 | 11.6 | 3.4 |
| Deaths, n (% of cases) | 77 (16) | 11 (9.8) | 6 (9.5) |
| Mortality rate | 5.3 | 2.5 | 1.1 |
| Severe outcome,d n (% of cases) | 260 (53) | 51 (46) | 19 (30) |
| Severe outcome rate | 18.5 | 12 | 3.4 |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Includes SARS-CoV-2 infections that occurred ≥14 days after the first dose of vaccine.
Includes SARS-CoV-2 infections that occurred ≥7 days after the second dose of vaccine.
Follow-up days are for the SARS-CoV-2 infection outcome. For the infection outcome, follow-up ends at the date of the infection. For the severe outcomes, follow-up ends at the date of the hospitalization or death. Individuals with SARS-CoV-2 infection who did not have a severe outcome were censored 30 days after the infection in the severe outcome analysis.
Includes hospitalization or death related to a SARS-CoV-2 infections. The counts are not mutually exclusive.